tiprankstipranks
Company Announcements

FibroBiologics Secures $25M Equity Agreement for Trials

Story Highlights

Don't Miss Our Christmas Offers:

The latest update is out from FibroBiologics, Inc. ( (FBLG) ).

FibroBiologics, Inc. announced a $25 million Standby Equity Purchase Agreement with YA II PN LTD., managed by Yorkville Advisors Global, LP, allowing the sale of its common stock over two years. This financing will support FibroBiologics in conducting its first-in-human trials for diabetic foot ulcers and IND-enabling studies for psoriasis, as well as further development of treatments for human longevity, multiple sclerosis, and cancer.

More about FibroBiologics, Inc.

Based in Houston, FibroBiologics is a clinical-stage biotechnology company focused on developing treatments and potential cures for chronic diseases using fibroblast cells and fibroblast-derived materials. The company holds over 160 patents and is advancing cell therapy research across multiple clinical pathways including disc degeneration, orthopedics, multiple sclerosis, psoriasis, wound healing, reversing organ involution, and cancer.

YTD Price Performance: -92.27%

Average Trading Volume: 170,998

Technical Sentiment Consensus Rating: Strong Buy

For an in-depth examination of FBLG stock, go to TipRanks’ Stock Analysis page.

Related Articles
TheFlyFibroBiologics announces $25M financing
TipRanks Auto-Generated NewsdeskFibroBiologics Resolves Commitments Through Share Issuance Agreement
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App